Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | K(lysine) acetyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.3926 | 0.3926 |
Loa Loa (eye worm) | hypothetical protein | 0.0056 | 0.1981 | 0.1981 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.017 | 0.949 | 1 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-B | 0.0054 | 0.1885 | 0.5 |
Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0178 | 1 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.1167 | 0.1073 |
Entamoeba histolytica | acetyltransferase, GNAT family | 0.0047 | 0.1416 | 0.5 |
Echinococcus multilocularis | zinc finger protein | 0.0028 | 0.0151 | 0.0047 |
Plasmodium vivax | histone acetyltransferase GCN5, putative | 0.0054 | 0.1885 | 0.5 |
Plasmodium falciparum | histone acetyltransferase GCN5 | 0.0047 | 0.1416 | 0.5 |
Schistosoma mansoni | zinc finger protein | 0.0028 | 0.0151 | 0.0047 |
Schistosoma mansoni | bromodomain containing protein | 0.0081 | 0.3618 | 0.355 |
Echinococcus granulosus | zinc finger protein | 0.0028 | 0.0151 | 0.0049 |
Brugia malayi | Bromodomain containing protein | 0.0095 | 0.4547 | 0.4215 |
Brugia malayi | Bromodomain containing protein | 0.0051 | 0.1636 | 0.1127 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.1167 | 0.1131 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0054 | 0.1885 | 0.1897 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0076 | 0.3334 | 0.3263 |
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0178 | 1 | 1 |
Giardia lamblia | Histone acetyltransferase GCN5 | 0.0047 | 0.1416 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.183 | 0.183 |
Loa Loa (eye worm) | acetyltransferase | 0.0178 | 1 | 1 |
Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.0054 | 0.1885 | 0.5 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0054 | 0.1885 | 0.5 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-A | 0.0054 | 0.1885 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.136 | 0.136 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0076 | 0.3334 | 0.344 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7943 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Potency (functional) | 1.2589 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.